Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This clinical trial will determine if subjects with heart failure with preserved ejection
fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2
(SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a
single blinded (to subject), randomized, parallel group, active controlled, single center
experimental design.